Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions

Biochemical Pharmacology

Volumn 120, Issue , 2016, Pages 72-82

  Banerjee, Mayukh ^a   Marensi, Vanessa ^a   Conseil, Gwenaëlle ^b   Le, X Chris ^a   Cole, Susan P C ^b   Leslie, Elaine M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Arsenic; ATP binding cassette transporter; Glutathione; MRP4 ABCC4; Non synonymous single nucleotide polymorphism; Prostaglandin E2

Indexed keywords

ANION; CACODYLIC ACID; ESTRADIOL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PROSTAGLANDIN E2; ABCC4 PROTEIN, HUMAN; ESTRADIOL-17 BETA-GLUCURONIDE; GLUTATHIONE; MONOMETHYLARSONOUS ACID; MULTIDRUG RESISTANCE PROTEIN; ORGANOARSENIC DERIVATIVE; ORGANOMETALLIC COMPOUND; POLLUTANT; RECOMBINANT PROTEIN;

ARTICLE; BIOTINYLATION; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; EMBRYO; ENDOPLASMIC RETICULUM; GENE MUTATION; GENETIC VARIABILITY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LLC PK1 CELL LINE; MEMBRANE VESICLE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; TRANSIENT TRANSFECTION; TRANSPORT ASSAY; AMINO ACID SUBSTITUTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOTRANSFORMATION; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; GENETICS; KIDNEY; METABOLISM; MUTATION; PIG; POLLUTANT; PROTEIN TRANSPORT;

AMINO ACID SUBSTITUTION; ANIMALS; ARSENICALS; BIOTRANSFORMATION; CACODYLIC ACID; CELL LINE; DINOPROSTONE; ENVIRONMENTAL POLLUTANTS; ESTRADIOL; GLUTATHIONE; HEK293 CELLS; HUMANS; KIDNEY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTAGENESIS, SITE-DIRECTED; MUTATION; ORGANOMETALLIC COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; SUS SCROFA;

EID: 84992488231     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.09.016     Document Type: Article

References (62)

1. [1] Naujokas, M.F., Anderson, B., Ahsan, H., Aposhian, H.V., Graziano, J.H., Thompson, C., Suk, W.A., The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ. Health Perspect. 121:3 (2013), 295–302.
2. [2] International Agency for Research on Cancer, A review of human carcinogens: C. Arsenic, Metals, Fibres and Dusts. 2012, World Health Organization Press, Lyon, France.
3. [3] Mondal, D., Banerjee, M., Kundu, M., Banerjee, N., Bhattacharya, U., Giri, A.K., Ganguli, B., Sen Roy, S., Polya, D.A., Comparison of drinking water, raw rice and cooking of rice as arsenic exposure routes in three contrasting areas of West Bengal, India. Environ. Geochem. Health 32:6 (2010), 463–477.
4. [4] Mabuchi, K., Lilienfeld, A.M., Snell, L.M., Cancer and occupational exposure to arsenic: a study of pesticide workers. Prev. Med. 9:1 (1980), 51–77.
5. [5] Paiva, L., Martinez, V., Creus, A., Quinteros, D., Marcos, R., Evaluation of micronucleus frequencies in blood lymphocytes from smelting plant workers exposed to arsenic. Environ. Mol. Mutagen. 49:3 (2008), 200–205.
6. [6] Kritharis, A., Bradley, T.P., Budman, D.R., The evolving use of arsenic in pharmacotherapy of malignant disease. Ann. Hematol. 92:6 (2013), 719–730.
7. [7] Mukhopadhyay, R., Bhattacharjee, H., Rosen, B.P., Aquaglyceroporins: generalized metalloid channels. Biochim. Biophys. Acta 1840:5 (2014), 1583–1591.
8. [8] Villa-Bellosta, R., Sorribas, V., Arsenate transport by sodium/phosphate cotransporter type IIb. Toxicol. Appl. Pharmacol. 247:1 (2010), 36–40.
9. [9] Cullen, W.R., Chemical mechanism of arsenic biomethylation. Chem. Res. Toxicol. 27:4 (2014), 457–461.
10. [10] Roggenbeck, B.A., Carew, M.W., Charrois, G.J., Douglas, D.N., Kneteman, N.M., Lu, X., Le, X.C., Leslie, E.M., Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes. Toxicol. Sci. 145:2 (2015), 307–320.
11. [11] Ghosh, P., Basu, A., Mahata, J., Basu, S., Sengupta, M., Das, J.K., Mukherjee, A., Sarkar, A.K., Mondal, L., Ray, K., Giri, A.K., Cytogenetic damage and genetic variants in the individuals susceptible to arsenic-induced cancer through drinking water. Int. J. Cancer 118:10 (2006), 2470–2478.
12. [12] Banerjee, M., Sarkar, J., Das, J.K., Mukherjee, A., Sarkar, A.K., Mondal, L., Giri, A.K., Polymorphism in the ERCC2 codon 751 is associated with arsenic-induced premalignant hyperkeratosis and significant chromosome aberrations. Carcinogenesis 28:3 (2007), 672–676.
13. [13] Ghosh, P., Banerjee, M., Giri, A.K., Ray, K., Toxicogenomics of arsenic: classical ideas and recent advances. Mutat. Res. 659:3 (2008), 293–301.
14. [14] Agusa, T., Fujihara, J., Takeshita, H., Iwata, H., Individual variations in inorganic arsenic metabolism associated with AS3MT genetic polymorphisms. Int. J. Mol. Sci. 12:4 (2011), 2351–2382.
15. III). Mol. Pharmacol. 86:2 (2014), 168–179.
16. [16] Slot, A.J., Molinski, S.V., Cole, S.P., Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 50:1 (2011), 179–207.
17. [17] Russel, F.G., Koenderink, J.B., Masereeuw, R., Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 29:4 (2008), 200–207.
18. [18] Reid, G., Wielinga, P., Zelcer, N., van der Heijden, I., Kuil, A., de Haas, M., Wijnholds, J., Borst, P., The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 9244–9249.
19. [19] Wen, J., Luo, J., Huang, W., Tang, J., Zhou, H., Zhang, W., The pharmacological and physiological role of multidrug-resistant protein 4. J. Pharmacol. Exp. Ther. 354:3 (2015), 358–375.
20. [20] Belleville-Rolland, T., Sassi, Y., Decouture, B., Dreano, E., Hulot, J.S., Gaussem, P., Bachelot-Loza, C., MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. Pharmacol. Res. 107 (2016), 381–389.
21. [21] Kool, M., de Haas, M., Scheffer, G.L., Scheper, R.J., van Eijk, M.J., Juijn, J.A., Baas, F., Borst, P., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:16 (1997), 3537–3547.
22. [22] Genomes Project Consortium, Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., Abecasis, G.R., A global reference for human genetic variation. Nature 526:7571 (2015), 68–74.
23. [23] Q. Liu, X. Lu, A. McKnight-Whitford, A. Popowich, Q. Zhang, X. Yan, M. Fricke, H. Sun, W.R. Cullen, X.C. Le, Synthesis and characterization of methylated and thiolated arsenic species for environmental and health sciences research, (submitted).
24. [24] Rius, M., Nies, A.T., Hummel-Eisenbeiss, J., Jedlitschky, G., Keppler, D., Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38:2 (2003), 374–384.
25. [25] Hoque, M.T., Cole, S.P., Down-regulation of Na+/H+ exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4. Cancer Res. 68:12 (2008), 4802–4809.
26. [26] El-Sheikh, A.A., van den Heuvel, J.J., Krieger, E., Russel, F.G., Koenderink, J.B., Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol. Pharmacol. 74:4 (2008), 964–971.
27. [27] Carew, M.W., Leslie, E.M., Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis 31:8 (2010), 1450–1455.
28. [28] Miah, M.F., Conseil, G., Cole, S.P., N-linked glycans do not affect plasma membrane localization of multidrug resistance protein 4 (MRP4) but selectively alter its prostaglandin E2 transport activity. Biochem. Biophys. Res. Commun. 469:4 (2016), 954–959.
29. +-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321:3 (2007), 1170–1178.
30. [30] Lipinski, T., Fitieh, A., St Pierre, J., Ostergaard, H.L., Bundle, D.R., Touret, N., Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. J. Immunol. 190:8 (2013), 4116–4128.
31. [31] Carew, M.W., Naranmandura, H., Shukalek, C.B., Le, X.C., Leslie, E.M., Monomethylarsenic diglutathione transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Drug Metab. Dispos. 39:12 (2011), 2298–2304.
32. [32] Kala, S.V., Neely, M.W., Kala, G., Prater, C.I., Atwood, D.W., Rice, J.S., Lieberman, M.W., The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 275:43 (2000), 33404–33408.
33. [33] Kalivas, J.H., Evaluation of volume and matrix effects for the generalized standard addition method. Talanta 34:11 (1987), 899–903.
34. [34] Csandl, M.A., Conseil, G., Cole, S.P., Cysteinyl leukotriene receptor 1/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (MRP1-4). Drug Metab. Dispos. 44:6 (2016), 857–866.
35. [35] Ansari, M., Sauty, G., Labuda, M., Gagne, V., Laverdiere, C., Moghrabi, A., Sinnett, D., Krajinovic, M., Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 114:7 (2009), 1383–1386.
36. [36] Ban, H., Andoh, A., Imaeda, H., Kobori, A., Bamba, S., Tsujikawa, T., Sasaki, M., Saito, Y., Fujiyama, Y., The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 45:10 (2010), 1014–1021.
37. [37] Krishnamurthy, P., Schwab, M., Takenaka, K., Nachagari, D., Morgan, J., Leslie, M., Du, W., Boyd, K., Cheok, M., Nakauchi, H., Marzolini, C., Kim, R.B., Poonkuzhali, B., Schuetz, E., Evans, W., Relling, M., Schuetz, J.D., Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 68:13 (2008), 4983–4989.
38. [38] Abla, N., Chinn, L.W., Nakamura, T., Liu, L., Huang, C.C., Johns, S.J., Kawamoto, M., Stryke, D., Taylor, T.R., Ferrin, T.E., Giacomini, K.M., Kroetz, D.L., The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J. Pharmacol. Exp. Ther. 325:3 (2008), 859–868.
39. [39] Janke, D., Mehralivand, S., Strand, D., Godtel-Armbrust, U., Habermeier, A., Gradhand, U., Fischer, C., Toliat, M.R., Fritz, P., Zanger, U.M., Schwab, M., Fromm, M.F., Nurnberg, P., Wojnowski, L., Closs, E.I., Lang, T., 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum. Mutat. 29:5 (2008), 659–669.
40. [40] Shen, S., Li, X.F., Cullen, W.R., Weinfeld, M., Le, X.C., Arsenic binding to proteins. Chem. Rev. 113:10 (2013), 7769–7792.
41. [41] Lin, Z.P., Zhu, Y.L., Johnson, D.R., Rice, K.P., Nottoli, T., Hains, B.C., McGrath, J., Waxman, S.G., Sartorelli, A.C., Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol. Pharmacol. 73:1 (2008), 243–251.
42. [42] Kochel, T.J., Fulton, A.M., Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat. 116–117 (2015), 99–103.
43. [43] Fletcher, J.I., Williams, R.T., Henderson, M.J., Norris, M.D., Haber, M., ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist. Update 26 (2016), 1–9.
44. [44] Conseil, G., Rothnie, A.J., Deeley, R.G., Cole, S.P., Multiple roles of charged amino acids in cytoplasmic loop 7 for expression and function of the multidrug and organic anion transporter MRP1 (ABCC1). Mol. Pharmacol. 75:2 (2009), 397–406.
45. [45] Iram, S.H., Cole, S.P., Mutation of Glu521 or Glu535 in cytoplasmic loop 5 causes differential misfolding in multiple domains of multidrug and organic anion transporter MRP1 (ABCC1). J. Biol. Chem. 287:10 (2012), 7543–7555.
46. [46] Hashimoto, K., Uchiumi, T., Konno, T., Ebihara, T., Nakamura, T., Wada, M., Sakisaka, S., Maniwa, F., Amachi, T., Ueda, K., Kuwano, M., Trafficking defect and functional defect by mutations of the ATP-binding domains in multidrug resistance protein 2 in patients with Dubin-Johnson syndrome. Hepatology 36 (2002), 1236–1245.
47. [47] Cheng, S.H., Gregory, R.J., Marshall, J., Paul, S., Souza, D.W., White, G.A., O'Riordan, C.R., Smith, A.E., Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990), 827–834.
48. [48] Gradhand, U., Lang, T., Schaeffeler, E., Glaeser, H., Tegude, H., Klein, K., Fritz, P., Jedlitschky, G., Kroemer, H.K., Bachmakov, I., Anwald, B., Kerb, R., Zanger, U.M., Eichelbaum, M., Schwab, M., Fromm, M.F., Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenom. J. 8:1 (2008), 42–52.
49. [49] Gow, J.M., Hodges, L.M., Chinn, L.W., Kroetz, D.L., Substrate-dependent effects of human ABCB1 coding polymorphisms. J. Pharmacol. Exp. Ther. 325:2 (2008), 435–442.
50. [50] Conseil, G., Cole, S.P., Two polymorphic variants of ABCC1 selectively alter drug resistance and inhibitor sensitivity of the multidrug and organic anion transporter multidrug resistance protein 1. Drug Metab. Dispos. 41:12 (2013), 2187–2196.
51. [51] Koike, K., Conseil, G., Leslie, E.M., Deeley, R.G., Cole, S.P., Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. J. Biol. Chem. 279:13 (2004), 12325–12336.
52. [52] Letourneau, I.J., Nakajima, A., Deeley, R.G., Cole, S.P., Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. Biochem. Pharmacol. 75:8 (2008), 1659–1669.
53. [53] Maeno, K., Nakajima, A., Conseil, G., Rothnie, A., Deeley, R.G., Cole, S.P., Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1). Drug Metab. Dispos. 37:7 (2009), 1411–1420.
54. [54] Tseng, C.H., Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 25:1 (2007), 1–22.
55. [55] McCarty, K.M., Chen, Y.C., Quamruzzaman, Q., Rahman, M., Mahiuddin, G., Hsueh, Y.M., Su, L., Smith, T., Ryan, L., Christiani, D.C., Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ. Health Perspect. 115:3 (2007), 341–345.
56. [56] Engstrom, K.S., Vahter, M., Fletcher, T., Leonardi, G., Goessler, W., Gurzau, E., Koppova, K., Rudnai, P., Kumar, R., Broberg, K., Genetic variation in arsenic (+3 oxidation state) methyltransferase (AS3MT), arsenic metabolism and risk of basal cell carcinoma in a European population. Environ. Mol. Mutagen. 56:1 (2015), 60–69.
57. [57] Antonelli, R., Shao, K., Thomas, D.J., Sams, R. 2nd, Cowden, J., AS3MT. GSTO, and PNP polymorphisms: impact on arsenic methylation and implications for disease susceptibility, Environ Res 132 (2014), 156–167.
58. [58] Ravna, A.W., Sager, G., Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorg. Med. Chem. Lett. 18:12 (2008), 3481–3483.
59. [59] Dawson, R.J.P., Locher, K.P., Structure of a bacterial multidrug ABC transporter. Nature 443:7108 (2006), 180–185.
60. [60] Kumar, P., Henikoff, S., Ng, P.C., Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4:7 (2009), 1073–1081.
61. [61] Adzhubei, I., Jordan, D.M., Sunyaev, S.R., Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet., 2013, 20.
62. [62] Capriotti, E., Altman, R.B., Bromberg, Y., Collective judgment predicts disease-associated single nucleotide variants. BMC Genom., 14(Suppl. 3), 2013, S2.